BAR502, a dual FXR and GPBAR1 agonist, promotes browning of white adipose tissue and reverses liver steatosis and fibrosis 1Scientific RepoRts | 7 42801 | DOI 10 1038/srep42801 www nature com/scientif[.]
www.nature.com/scientificreports OPEN received: 14 October 2016 accepted: 13 January 2017 Published: 16 February 2017 BAR502, a dual FXR and GPBAR1 agonist, promotes browning of white adipose tissue and reverses liver steatosis and fibrosis Adriana Carino1,*, Sabrina Cipriani2,*, Silvia Marchianò1, Michele Biagioli1, Chiara Santorelli1, Annibale Donini1, Angela Zampella3, Maria Chiara Monti4 & Stefano Fiorucci1 Non-alcoholic steatohepatitis (NASH) is a highly prevalent chronic liver disease Here, we have investigated whether BAR502, a non-bile acid, steroidal dual ligand for FXR and GPBAR1, reverses steato-hepatitis in mice fed a high fat diet (HFD) and fructose After week, mice on HFD gained ≈30% of b.w (P